Thiabendazole

Thiabendazole

SCHEMBL625588

c1ccc2[nH]c(-c3cscn3)nc2c1.c1ccc2[nH]c(-c3cscn3)nc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 9/20 1.00
METAP2 P50579 7/20 1.00
NPC1 O15118 6/20 1.00
RAB9A P51151 6/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
TP53 P04637 4/20 1.00
KDM4E B2RXH2 3/20 1.00
FKBP1A P62942 2/20 1.00
ADORA3 P0DMS8 2/20 1.00
TSHR P16473 2/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C19 P33261 1/20 1.00
HIF1A Q16665 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
HDAC6 Q9UBN7 1/20 1.00
PKM P14618 3/20 0.58
HPGD P15428 2/20 0.58
LMNA P02545 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiabendazole SCHEMBL19842 1.00 METAP1 (1.00) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL29370729 1.00 METAP1 (1.00) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL5184037 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL2314460 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL11218788 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL7733801 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL28861440 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL9856779 0.98 METAP1 (0.97) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL675655 0.91 METAP1 (0.83) METAP1METAP2NPC1RAB9ASMN1; SMN2
Thiabendazole SCHEMBL675656 0.91 METAP1 (0.83) METAP1METAP2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772009-B2 Room temperature phosphorescence apparatus and methods SCR Research, LLC (US) 2010-08-10 US claimed
WO-2007061574-A2 ROOM TEMPERATURE PHOSPHORESCENCE APPARATUS AND METHODS SCA RESEARCH, LLC (US) 2007-05-31 WO claimed
US-20070117215-A1 Room temperature phosphorescence apparatus and methods POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2007-05-24 US claimed
CN-109310093-A Natamycin composition and application thereof AREC作物保护有限公司 2019-02-05 CN disclosed
US-9951205-B2 Stable compositions of thiabendazole and iodine-containing fungicides LANXESS DEUTSCHLAND GMBH (DE) 2018-04-24 US disclosed
CN-104204057-B Thiabendazole and the stable compositions containing iodine antifungal 朗盛德国有限责任公司 2016-10-05 CN disclosed
US-9296878-B2 Fungicide formulations for plasticized PVC LANXESS DEUTSCHLAND GMBH (DE) 2016-03-29 US disclosed
US-20150203660-A1 FUNGICIDE FORMULATIONS FOR PLASTICIZED PVC LANXESS DEUTSCHLAND GMBH (DE) 2015-07-23 US disclosed
US-20150051279-A1 STABLE COMPOSITIONS OF THIABENDAZOLE AND IODINE-CONTAINING FUNGICIDES LANXESS DEUTSCHLAND GMBH (DE) 2015-02-19 US disclosed
EP-2637501-A2 FUNGICIDAL COMPOSITIONS AND METHODS OF USE The Board Of Trustees Of The University Of Alabama (US) 2013-09-18 EP disclosed
US-20120264605-A1 Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2012-10-18 US disclosed
WO-2007061574-A2 ROOM TEMPERATURE PHOSPHORESCENCE APPARATUS AND METHODS SCA RESEARCH, LLC (US) 2007-05-31 WO disclosed
US-20070117215-A1 Room temperature phosphorescence apparatus and methods POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2007-05-24 US disclosed
WO-2007044693-A2 MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS THE UNIVERSITY OF ALABAMA (US) 2007-04-19 WO disclosed
EP-1375354-A1 PACKAGED FOOD PRODUCT AND PRODUCTION METHOD THEREFOR Resticas del Guadalquivir, S.A. (ES) 2004-01-02 EP disclosed
US-5948421-A Aqueous liquid agricultural composition KAO CORPORATION (JP) 1999-09-07 US disclosed
US-5757278-A Personal verification system KABUSHIKI KAISHA TOSHIBA (JP) 1998-05-26 US disclosed
WO-1997036471-A1 GELATIN-BASED COATINGS FOR PLANT SEEDS AND PROPAGULES MONSANTO COMPANY (US) 1997-10-09 WO disclosed
WO-1996015107-A1 DITHIOCARBAMATE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1996-05-23 WO disclosed
EP-0617074-A1 Alveolar cellulose material containing a biocide FINANCIERE ELYSEES BALZAC (FR) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264605-A1 Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients SLC5A6, PNLIP, IPMK METAP1 1967/4885METAP2 1443/4885NPC1 295/4885
US-20150051279-A1 STABLE COMPOSITIONS OF THIABENDAZOLE AND IODINE-CONTAINING FUNGICIDES DDT, TPO, TRHDE METAP1 3898/4885METAP2 3357/4885NPC1 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.